Activity Report for Quarter Ended September 30, 2026 (Appendix 4C)

manilatimes.net · 2026-10-29

NEW YORK, Oct. 28, 2026 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory diseases, today provided its activity report for the first fiscal quarter ended September 30, 2026.

Read the full story at manilatimes.net →